Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of DBV.PA is 3.9 and suggests 3% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell